Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development

 

 

 

 

 

 

Synergistic antitumor exercise of a DLL4/VEGF bispecific therapeutic antibody together with irinotecan in gastric most cancers

 

PSMB8 antibody
70R-19589	Fitzgerald	50 ul	EUR 522
Description: Rabbit polyclonal PSMB8 antibody

PSMB8 Antibody
1-CSB-PA116429	Cusabio	EUR 380.40 EUR 292.80	100ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

PSMB8 Antibody
1-CSB-PA018886GA01HU	Cusabio	EUR 716.40 EUR 399.60	150ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF

PSMB8 Antibody
1-CSB-PA018886LA01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

PSMB8 Antibody
1-CSB-PA775839	Cusabio	EUR 380.40 EUR 292.80	100ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100

PSMB8 Conjugated Antibody
C43134	SAB	100ul	EUR 476.4

PSMB8 Polyclonal Antibody
A73468	EpiGentek	EUR 377.30 EUR 577.50	50 ul 100 ul

PSMB8 Antibody, HRP conjugated
1-CSB-PA018886LB01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

PSMB8 Antibody, FITC conjugated
1-CSB-PA018886LC01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

PSMB8 Antibody, Biotin conjugated
1-CSB-PA018886LD01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Monoclonal PSMB8 Antibody, Clone: 1A5
AMM02864G	Leading Biology	0.1ml	EUR 633.6
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E

Psmb8/ Rat Psmb8 ELISA Kit
ELI-15652r	Lifescience Market	96 Tests	EUR 1063.2

Proteasome subunit beta type-8 (PSMB8) Antibody
20-abx211178	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Proteasome subunit beta type-8 (PSMB8) Antibody
20-abx211851	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
20-abx141396	Abbexa	EUR 444.00 EUR 727.20 EUR 360.00	100 ul 200 ul 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
20-abx114776	Abbexa	EUR 878.40 EUR 477.60	150 ul 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
abx028154-400ul	Abbexa	400 ul	EUR 627.6

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
abx028154-80l	Abbexa	80 µl	EUR 343.2

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
20-abx006453	Abbexa	EUR 493.20 EUR 710.40 EUR 218.40 EUR 376.80	100 ul 200 ul 20 ul 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
abx011689-100ul	Abbexa	100 ul	EUR 493.2

Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3
AMM03954G	Leading Biology	0.1mg	EUR 580.8
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E

PSMB8 siRNA
20-abx930156	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

PSMB8 siRNA
20-abx930157	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

PSMB8 siRNA
20-abx904317	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

PSMB8 Rabbit pAb
A7340-100ul	Abclonal	100 ul	EUR 369.6

PSMB8 Rabbit pAb
A7340-200ul	Abclonal	200 ul	EUR 550.8

PSMB8 Rabbit pAb
A7340-20ul	Abclonal	20 ul	EUR 219.6

PSMB8 Rabbit pAb
A7340-50ul	Abclonal	50 ul	EUR 267.6

PSMB8 Blocking Peptide
BF0434-BP	Affbiotech	1mg	EUR 234

PSMB8 protein (His tag)
80R-2608	Fitzgerald	100 ug	EUR 386.4
Description: Purified recombinant PSMB8 protein

Canine PSMB8 ELISA KIT
ELI-15651d	Lifescience Market	96 Tests	EUR 1113.6

Rat PSMB8 shRNA Plasmid
20-abx984734	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

Human PSMB8 shRNA Plasmid
20-abx953843	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

Mouse PSMB8 shRNA Plasmid
20-abx971337	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

PSMB8 Recombinant Protein (Rat)
RP222629	ABM	100 ug	Ask for price

PSMB8 Recombinant Protein (Mouse)
RP165287	ABM	100 ug	Ask for price

PSMB8 Recombinant Protein (Human)
RP085356	ABM	100 ug	Ask for price

Psmb8 ORF Vector (Rat) (pORF)
ORF074211	ABM	1.0 ug DNA	EUR 607.2

PSMB8 ORF Vector (Human) (pORF)
ORF028453	ABM	1.0 ug DNA	EUR 486

Psmb8 ORF Vector (Mouse) (pORF)
ORF055097	ABM	1.0 ug DNA	EUR 607.2

[KO Validated] PSMB8 Rabbit pAb
A19933-100ul	Abclonal	100 ul	EUR 492

[KO Validated] PSMB8 Rabbit pAb
A19933-200ul	Abclonal	200 ul	EUR 685.2

[KO Validated] PSMB8 Rabbit pAb
A19933-20ul	Abclonal	20 ul	EUR 265.2

[KO Validated] PSMB8 Rabbit pAb
A19933-50ul	Abclonal	50 ul	EUR 344.4

PSMB8 ELISA Kit (Dog) (OKEH03975)
OKEH03975	Aviva Systems Biology	96 Wells	EUR 1012.8
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL

PSMB8 ELISA Kit (Human) (OKEH07770)
OKEH07770	Aviva Systems Biology	96 Wells	EUR 1310.4
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL

PSMB8 ELISA Kit (Human) (OKCD02695)
OKCD02695	Aviva Systems Biology	96 Wells	EUR 950.4
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL

Psmb8 sgRNA CRISPR Lentivector set (Rat)
K6921501	ABM	3 x 1.0 ug	EUR 406.8

PSMB8 sgRNA CRISPR Lentivector set (Human)
K1740301	ABM	3 x 1.0 ug	EUR 406.8

Psmb8 sgRNA CRISPR Lentivector set (Mouse)
K4425601	ABM	3 x 1.0 ug	EUR 406.8

Psmb8 3'UTR GFP Stable Cell Line
TU167173	ABM	1.0 ml	Ask for price

PSMB8 3'UTR GFP Stable Cell Line
TU069046	ABM	1.0 ml	EUR 1672.8

Psmb8 3'UTR GFP Stable Cell Line
TU266964	ABM	1.0 ml	Ask for price

PSMB8 Protein Vector (Rat) (pPM-C-HA)
PV296844	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Rat) (pPB-C-His)
PV296842	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Rat) (pPB-N-His)
PV296843	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Rat) (pPM-C-His)
PV296845	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Human) (pPM-C-HA)
PV113812	ABM	500 ng	EUR 662.4

PSMB8 Protein Vector (Mouse) (pPM-C-HA)
PV220388	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Human) (pPB-C-His)
PV113810	ABM	500 ng	EUR 662.4

PSMB8 Protein Vector (Human) (pPB-N-His)
PV113811	ABM	500 ng	EUR 662.4

PSMB8 Protein Vector (Human) (pPM-C-His)
PV113813	ABM	500 ng	EUR 662.4

PSMB8 Protein Vector (Mouse) (pPB-C-His)
PV220386	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Mouse) (pPB-N-His)
PV220387	ABM	500 ng	EUR 723.6

PSMB8 Protein Vector (Mouse) (pPM-C-His)
PV220389	ABM	500 ng	EUR 723.6

Psmb8 3'UTR Luciferase Stable Cell Line
TU117173	ABM	1.0 ml	Ask for price

PSMB8 3'UTR Luciferase Stable Cell Line
TU019046	ABM	1.0 ml	EUR 1672.8

 

Notch signaling has been recognized as a vital pathway in gastric most cancers (GC) development and metastasis, and inhibition of Delta-like ligand 4 (DLL4), a Notch ligand, is usually recommended as a potent therapeutic strategy for GC. Expression of each DLL4 and vascular endothelial development issue receptor 2 (VEGFR2) was related within the malignant tissues of GC sufferers.

• • We centered on vascular endothelial development issue (VEGF), a recognized angiogenesis regulator and activator of DLL4. Right here, we used ABL001, a DLL4/VEGF bispecific therapeutic antibody, and investigated its therapeutic impact in GC.

 

• • Remedy with human DLL4 therapeutic antibody (anti-hDLL4) or ABL001 barely diminished GC cell development in monolayer tradition; nonetheless, they considerably inhibited cell development in 3D-culture, suggesting a discount within the most cancers stem cell inhabitants. Remedy with anti-hDLL4 or ABL001 additionally decreased GC cell migration and invasion.

 

• • Furthermore, the mixed therapy of irinotecan with anti-hDLL4 or ABL001 confirmed synergistic antitumor exercise. Each mixture remedies additional diminished cell development in 3D-culture in addition to cell invasion. Apparently, the mix therapy of ABL001 with irinotecan synergistically diminished the GC burden in each xenograft and orthotopic mouse fashions.

 

• Collectively, DLL4 inhibition considerably decreased cell motility and stem-like phenotype and the mix therapy of DLL4/VEGF bispecific therapeutic antibody with irinotecan synergistically diminished the GC burden in mouse fashions. Our information recommend that ABL001 doubtlessly represents a potent agent in GC remedy. Additional biochemical and pre-clinical research are wanted for its software within the clinic.